Difference between revisions of "Hodi FS, et al. N. Engl. J. Med. (2010) cited as Ref 642 in DOI: 10.1038/s41392-020-0110-5 (Q9905)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: First Author string (P149): Hodi FS, #quickstatements; #temporary_batch_1589996169159)
(‎Created claim: Page(s) (P105): 711-723, #quickstatements; #temporary_batch_1590074839150)
 
(6 intermediate revisions by the same user not shown)
Property / DOI Identifier
 +
Property / DOI Identifier: 10.1056/NEJMoa1003466 / rank
 +
Normal rank
Property / PubMed ID
 +
Property / PubMed ID: 20525992 / rank
 +
Normal rank
Property / Publication Date
 +
2010
Timestamp+2010-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2010 / rank
 +
Normal rank
Property / Published In Name String
 +
N. Engl. J. Med.
Property / Published In Name String: N. Engl. J. Med. / rank
 +
Normal rank
Property / Volume
 +
363
Property / Volume: 363 / rank
 +
Normal rank
Property / title
 +
Improved survival with ipilimumab in patients with metastatic melanoma (English)
Property / title: Improved survival with ipilimumab in patients with metastatic melanoma (English) / rank
 +
Normal rank
Property / Page(s)
 +
711-723
Property / Page(s): 711-723 / rank
 +
Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Hodi FS, et al. N. Engl. J. Med. (2010) cited as Ref 642 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Hodi FS
    0 references
    0 references
    2010
    0 references
    N. Engl. J. Med.
    0 references
    363
    0 references
    Improved survival with ipilimumab in patients with metastatic melanoma (English)
    0 references
    711-723
    0 references